Axsome Therapeutics Stock Current Ratio
| AXSM Stock | USD 169.38 1.83 1.09% |
Fundamental analysis of Axsome Therapeutics allows traders to better anticipate movements in Axsome Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 2.42 | 2.30 |
Axsome | Current Ratio | Build AI portfolio with Axsome Stock |
Axsome Therapeutics Company Current Ratio Analysis
Axsome Therapeutics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Axsome Therapeutics Current Ratio | 2.44 X |
Most of Axsome Therapeutics' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Axsome Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Axsome Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Axsome Therapeutics is extremely important. It helps to project a fair market value of Axsome Stock properly, considering its historical fundamentals such as Current Ratio. Since Axsome Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Axsome Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Axsome Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Axsome Price To Sales Ratio
Price To Sales Ratio |
|
In accordance with the recently published financial statements, Axsome Therapeutics has a Current Ratio of 2.44 times. This is 16.15% lower than that of the Pharmaceuticals sector and 65.14% lower than that of the Health Care industry. The current ratio for all United States stocks is 12.96% lower than that of the firm.
Axsome Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Axsome Therapeutics' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Axsome Therapeutics could also be used in its relative valuation, which is a method of valuing Axsome Therapeutics by comparing valuation metrics of similar companies.Axsome Therapeutics is currently under evaluation in current ratio category among its peers.
Axsome Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Axsome Therapeutics from analyzing Axsome Therapeutics' financial statements. These drivers represent accounts that assess Axsome Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Axsome Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 3.0B | 1.4B | 3.1B | 3.6B | 3.3B | 3.4B | |
| Enterprise Value | 2.9B | 1.4B | 3.0B | 3.4B | 3.1B | 3.2B |
Axsome Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Axsome Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Axsome Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Axsome Fundamentals
| Return On Equity | -2.75 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (0.41) % | ||||
| Operating Margin | (0.19) % | ||||
| Current Valuation | 8.34 B | ||||
| Shares Outstanding | 50.41 M | ||||
| Shares Owned By Insiders | 15.69 % | ||||
| Shares Owned By Institutions | 76.63 % | ||||
| Number Of Shares Shorted | 2.84 M | ||||
| Price To Earning | (3.34) X | ||||
| Price To Book | 114.57 X | ||||
| Price To Sales | 15.05 X | ||||
| Revenue | 385.69 M | ||||
| Gross Profit | 515.6 M | ||||
| EBITDA | (272.6 M) | ||||
| Net Income | (287.22 M) | ||||
| Cash And Equivalents | 73.39 M | ||||
| Cash Per Share | 1.82 X | ||||
| Total Debt | 192.96 M | ||||
| Debt To Equity | 6.20 % | ||||
| Current Ratio | 2.44 X | ||||
| Book Value Per Share | 1.47 X | ||||
| Cash Flow From Operations | (128.41 M) | ||||
| Short Ratio | 5.36 X | ||||
| Earnings Per Share | (4.67) X | ||||
| Target Price | 197.59 | ||||
| Number Of Employees | 816 | ||||
| Beta | 0.43 | ||||
| Market Capitalization | 8.45 B | ||||
| Total Asset | 568.5 M | ||||
| Retained Earnings | (1.12 B) | ||||
| Working Capital | 254.96 M | ||||
| Current Asset | 34.76 M | ||||
| Current Liabilities | 6.74 M | ||||
| Net Asset | 568.5 M |
About Axsome Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Axsome Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Axsome Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Axsome Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Axsome Therapeutics Piotroski F Score and Axsome Therapeutics Altman Z Score analysis. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.67) | Revenue Per Share | Quarterly Revenue Growth 0.632 | Return On Assets | Return On Equity |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.